T1	HMM 29 48	efficacy and safety
T2	HMM 761 798	was in-segment binary restenosis rate
T3	HMM 858 1060	included target vessel failure (TVF; including cardiac death, myocardial infarction, and target vessel revascularization) and Academic Research Consortium-defined definite/probable stent thrombosis (ST)
T4	HMM 1143 1151	endpoint
T5	HMM 1393 1404	the rate of
